fig4

Overcoming resistance to anti-PD-1/PD-L1 therapy in cancer

Figure 4. ORRs for PD-1/PD-L1 inhibitors as monotherapy. Purple circles show ORRs for PD-1/PD-L1 inhibitors as first-line treatment; pink circles show ORRs for their use in subsequent therapy; yellow circles show ORRs regardless of treatment line. *Tumors are microsatellite instability-high or mismatch repair-deficient. Created in BioRender. li, L. (2026) https://BioRender.com/kws7r1d. ORRs: Objective response rates; PD-1: programmed death-1; PD-L1: programmed death-ligand 1; MSI-H: microsatellite instability-high; dMMR: mismatch repair deficiency.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/